Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice
Hedda C Lamers, Erika Van Nieuwenhove, Sebastiaan J Vastert, Marc H A Jansen, Annet van Royen-Kerkhof, Joost F Swart, Sytze de Roock · 2025
Read Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice by Hedda C Lamers, Erika Van Nieuwenhove, Sebastiaan J Vastert, Marc H A Jansen, Annet van Royen-Kerkhof, Joost F Swart, Sytze de Roock (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12750840.txt.
Description
Hedda Lamers and co-authors charted how new targeted drugs entered routine care for children with joint arthritis, in a 2025 study. Biologic and targeted synthetic drugs have widened options for juvenile idiopathic arthritis, the childhood form. The team pulled prescription records from the largest Dutch children's rheumatology center, covering 2012 to 2023.
First prescriptions numbered 672 for the targeted drugs and 720 for older standard ones, across 696 patients. One drug family, TNF-alpha blockers, took about 79 percent of the targeted share. Targeted prescribing grew over the period, and the authors align the shifts with approval dates and rule changes from the European regulator.
Catalog record
| CREATOR | Hedda C Lamers, Erika Van Nieuwenhove, Sebastiaan J Vastert, Marc H A Jansen, Annet van Royen-Kerkhof, Joost F Swart, Sytze de Roock |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |